Crossmark

Sintilimab plus lenvatinib in combination with transarterial chemoembolization and subsequent radiofrequency ablation for unresectable hepatocellular carcinoma: a single-arm, single-center study

Crossref DOI link: https://doi.org/10.1038/s41598-025-12858-y

Published Online: 2025-07-25

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Chen, Xiaochun

Wang, Changping

Tang, Yuanjie

Sun, Haoyan

Liu, Hongling

Lin, Chuan

Yuan, Zhiping
Funding

Funding for this research was provided by:

Health Commission of Sichuan Province Medical Science and Technology Program (24WSXT074)

National Anti-Tumor Drug Surveillance System of National Cancer Center (DSS-YSF-202311)

Wu Jieping Medical Foundation (320.6750.2022-01-11)
License Information

Text and Data Mining valid from 2025-07-25

Version of Record valid from 2025-07-25
More Information

Article History

Received: 27 December 2024

Accepted: 21 July 2025

First Online: 25 July 2025

Declarations

:

: The authors declare no competing interests.

: This study received ethical approval from the Institutional Review Board of Yibin First People’s Hospital (Sichuan, China) and was conducted in accordance with the Declaration of Helsinki, clinical practice guidelines for liver cancer treatment, and pertinent legal and regulatory standards. All participants provided written informed consent.

Document is current

Any future updates will be listed below